We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 34.72%
This Fund
S&P 500
This Quarter Est. Return
-2.25%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$524M
AUM Growth
-$65.4M
Cap. Flow
-$51.4M
Cap. Flow %
-9.8%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
LCTX icon
Lineage Cell Therapeutics
LCTX
+$7.21M
2
IMDX
Insight Molecular Diagnostics
IMDX
+$2.45M

Top Sells

Rank Stock Value
1
CYNO
Cynosure, Inc. Class A
CYNO
+$61.1M

Sector Composition

Rank Sector Weight
1 Healthcare 46.73%
2 Consumer Staples 42.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNST icon
1
Monster Beverage
MNST
$94.3B
$221M 42.23%
9,594,816
– –
STAA icon
2
STAAR Surgical
STAA
$1.21B
$106M 20.28%
10,855,179
– –
LCTX icon
3
Lineage Cell Therapeutics
LCTX
$269M
$93.6M 17.84%
30,997,307
+2,539,999
+9% +$7.21M
IWM icon
4
iShares Russell 2000 ETF
IWM
$79.8B
$57.7M 11.01%
420,000
– –
IMDX
5
Insight Molecular Diagnostics
IMDX
$150M
$18.2M 3.47%
152,834
+21,250
+16% +$2.45M
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$14.4M 2.74%
322,411
– –
AST
7
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$12.6M 2.4%
3,699,848
– –
AST.WS
8
DELISTED
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
$140K 0.03%
328,205
– –
CYNO
9
DELISTED
Cynosure, Inc. Class A
CYNO
– –
-1,338,827
Closed -$61.1M

Similar funds

PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.41B AUM 18.71% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return

Broadwood Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Broadwood Capital held 9 positions worth $524M, down 11% from $590M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital withdrew a net $51.4M in Q1 2017, closing 1 position. Its most notable exit was Cynosure, Inc. Class A, an estimated $61.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 44% a quarter earlier, followed by Consumer Staples.

Against the trend, Broadwood Capital added an estimated $7.21M to Lineage Cell Therapeutics.

  • Broadwood Capital added most to Lineage Cell Therapeutics in Q1 2017, an estimated $7.21M increase.
  • Broadwood Capital fully exited Cynosure, Inc. Class A in Q1 2017, selling an estimated $61.1M.
  • Broadwood Capital's ten largest holdings make up 100% of its $524M portfolio in Q1 2017.
  • Broadwood Capital opened 0 new positions and closed 1 in Q1 2017.
  • Broadwood Capital's portfolio value fell 11% quarter-over-quarter to $524M.

Based on Broadwood Capital's 13F filing for Q1 2017, filed 15 May 2017.